Phaseline

Companies › AdipoPharma

AdipoPharma: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Metabolic and endocrine; next expected readout May 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
PATAS Trifluoroacetate
Modulator of ALMS1-PKC alpha interaction
ALMS1, PRKCAPhase 1Type 2 DiabetesMay 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07223333PATAS TrifluoroacetatePhase 1Type 2 DiabetesMetabolic and endocrineMay 2027

Targets

ALMS1 (1) PRKCA (1)

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.